On the evening of April 15, Brightgene Bio-Medical Technology Co.Ltd(688166) released the annual report of 2021. In 2021, the company achieved an operating revenue of 1.052 billion yuan, a year-on-year increase of 34%; The net profit attributable to the shareholders of the listed company was 244 million yuan, a year-on-year increase of 43.60%; The basic income per share is 0.6 yuan / share. The company plans to distribute a cash dividend of 1.2 yuan (including tax) for every 10 shares.
During the reporting period, the company’s main business income increased rapidly. The company achieved product sales revenue of 9277953 million yuan, an increase of 38.38% over the same period of last year, and the gross profit margin of product sales was 53.07%, an increase of 3.30 percentage points over the same period of last year. In addition, during the reporting period, the company’s technical service orders completed milestone delivery. At the same time, the company actively developed ADC pharmaceutical technology service demand customers, realizing a technical revenue of 677785 million yuan, an increase of 44.17% over the same period of last year.
In terms of R & D innovation, the company has continuously increased R & D investment, with R & D expenses of 173289600 yuan, a year-on-year increase of 23.04%, and R & D expenses accounting for 16.47% of operating revenue. The company focuses on building long-term PDC coupling technology platform, non biological macromolecule technology platform and inhalation preparation platform, developing innovative drugs with global independent intellectual property rights in the field of tumor immunity and targeted therapy, and building an internationally competitive product line in the field of respiratory inhalation. At the same time, the company implements the layout of the whole industry chain, pays attention to the change opportunities of the pharmaceutical supporting industry, and extends vertically to the fields of special excipients for oral medicine, high-end excipients for injection and biological health products.
Lay a solid foundation for the sustainable development of the industrial chain. On the one hand, the company has set up factories overseas, relying on its own technical ability and combined with the local market situation to develop marketable products and expand the overseas market; On the other hand, the company actively tracks the global cutting-edge technology and invests in innovative technology companies with potential to lay out innovative drug pipelines for the future.
Brightgene Bio-Medical Technology Co.Ltd(688166) said that in the future, the company will actively participate in international exchanges and cooperation with an open mind and implement the two-way strategy of “going out and bringing in”. The “going out” strategy is divided into two parts. On the one hand, it is to build a preparation production quality system with European and American cGMP standards to market high-quality preparation products around the world. On the other hand, it is to strive to license its own technical achievements to foreign companies to realize technology output and income.
